MLAB Mesa Laboratories Inc.

Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure

Mesa Laboratories, Inc. Reports Immaterial Financial Exposure to Silicon Valley Bank Closure

LAKEWOOD, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”) is a global leader in the design and manufacture of life science tools and critical quality control solutions. Mesa has monitored the situation at Silicon Valley Bank (“SVB”), whereby on March 10, 2023, the California Department of Financial Protection and Innovation closed SVB and placed it under control of the United States Federal Deposit Insurance Corporation (“FDIC”) as receiver.  According to the FDIC,  depositors will have access to all of their money starting Monday, March 13, 2023.

Mesa has taken proactive steps to mitigate risk to the Company, which continues to believe that its existing cash and cash equivalents balance and cash flow from operations will be sufficient to meet its working capital, capital expenditures, and material cash requirements from known contractual obligations for the foreseeable future.

Mesa’s deposit accounts held at SVB in excess of the $250,000 FDIC-insured limits are less than $500,000. Mesa believes this is immaterial when compared to the Company’s total balance of cash and cash equivalents which were $26.1 million as of December 31, 2022 and are held on deposit at multiple large financial institutions across the world. Other than the deposit accounts noted, Mesa has no material positions or relationships with SVB.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries.  Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Clinical Genomics, and Calibration Solutions) to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.



Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc.,  

For more information about the Company, please visit its website at 
EN
13/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesa Laboratories Inc.

 PRESS RELEASE

Mesa Laboratories Executes Previously-Announced Strategic Financing Pl...

Mesa Laboratories Executes Previously-Announced Strategic Financing Plan LAKEWOOD, Colo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate principal of the Company’s 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). On August 12, 2025, the Company drew $97.0 million under its existing Amended and Restated Credit Agreement (the “Credit Agreement”), bringing the total outstanding balance to $108...

 PRESS RELEASE

Mesa Labs Announces First Quarter Results

Mesa Labs Announces First Quarter Results LAKEWOOD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q26”) ended June 30, 2025 (amounts in thousands). First quarter FY26 compared to first quarter FY25: Revenues increased 2.4%Non-GAAP core organic revenues1 growth was 0.4% Operating income decreased 45.1% to $3,064 primarily due to the impacts of FX and non-cash stock-based compensation ...

 PRESS RELEASE

MESA LABS DECLARES QUARTERLY DIVIDEND

MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the p...

 PRESS RELEASE

Mesa Laboratories, Inc. to Announce First Quarter Results on August 5,...

Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025 LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and servic...

 PRESS RELEASE

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q25”) and full fiscal year (“FY25”) ended March 31, 2025 (amounts in thousands). Fourth quarter FY25 compared to fourth quarter FY24: Revenues increased 5.5%Non-GAAP core organic revenues growth1 was 6.3%Operating income increased 100.5% to $1,469Non-GAA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch